// App-Quantinova.ai

: Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy

Researchers

Presenter

  • Philipp Bernhard Staber

Principal Investigators

  • Asher A. Chanan-Khan

  • Talha Munir

  • Dietger Niederweiser

  • Johannes Schetelig

  • Jan Moritz Middeke

  • Maren Dirnberger-Hertweck

  • Peter Kelemen

  • Johannes Weirather

  • Sameer A. Parikh

  • Stephan Stilgenbauer

  • Clemens-Martin Wendtner

  • Jennifer A. Woyach

Medical Centers

  • Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

  • Mayo Clinic, Jacksonville, FL

  • Dept. Hematology and Cell Therapy,University Hospital Leipzig,Leipzig,Germania

  • Medizinische Klinik und Poliklinik I, TU Dresden, Dresden, Germany

  • Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus, Dresden, Germany

  • MorphoSys AG, Planegg, Germany

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

Locations

  • Austria

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Bruton tyrosine kinase

Drug/Treatment

  • Venetoclax

  • Tafasitamab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved